Cancer Biomarker Profiling Using Nanozyme Containing Iron Oxide Loaded with Gold Particles

Victor Akpe*1,2, Muhammad J.A. Shiddiky*1,3, Tak H. Kim1,2, Christopher L. Brown1,2, Yusuke Yamauchi4, Ian E. Cock*1,2

Affiliations

1 School of Environment and Science, Griffith University, Nathan Campus, QLD 4111, Australia.
2 Environmental Futures Research Institute, Griffith University, Nathan Campus, QLD 4111, Australia.
3 Queensland Micro and Nanotechnology Centre, Griffith University, Nathan, Queensland 4111, Australia, Griffith University, Nathan Campus, QLD 4111, Australia.
4 School of Chemical Engineering and Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, Brisbane, QLD 4072, Australia.

* Corresponding Author

Email: I.Cock@griffith.edu.au

Conflict-of-interest: All authors declare no conflict of interest
Abstract

Nanozymes are nanomaterials with intrinsic magnetism and superparamagnetic properties. In the presence of an external magnet, nanozyme particles aggregate and redisperse without a foreign attraction. We evaluated the performances of nanozyme by changing the biosensing platforms and substituting other biological variants for a complete cancer assay detection. We investigated the expression of morphological variants in the transmission of signals using an electrochemical method. The signal responses, including signal enhancement with the nanozyme (Au-Fe$_2$O$_3$), showed a wide capturing range (> 80 %, from $10^2$ - $10^5$ cells / mL in PBS buffer, pH 7.4). The platform showed a fast response time within a dynamic range of 10 - $10^5$ cells / mL for the investigated T47D cancer cell line. We also obtained higher responses for anti-HER2 (Human Epidermal Receptor 2)/streptavidin interface as the biosensing electrode in the presence of T47D cancer cells. The positive assay produced a 6-fold increase in current output compared to the negative target or negative biological variant. We calculated the limit of detection, LOD at 0.4 U/mL, and quantitation, LOQ at 4 U/mL (units per milliliter). However, blood volume amounts in clinical settings may constrain diagnosis and increase detection limit value significantly.

**Keywords:** Amperometry Detection, Cancer Biomarkers, Limit of Detection, Biosensor Amplification,

1. Introduction

Cancer biomarkers are increasingly relevant in diagnostic, prognostic, and therapeutic evaluations of patient survival and long-term clinical management. Biomarkers are biological tools use for mapping the metastatic cascade *in vitro* and *in vivo* environments. More recently, interest in cancer-based interface technologies is expanding the detection of early-stage disease [1]. However, cancer cells are highly heterogeneous, and the quantitative profiling of biomarkers using analytical methods of detection becomes imperative.

Some of the standard techniques for profiling biomarkers include electrochemical, fluorescence, surface-enhanced Raman scattering (SERS), and surface plasmon resonance (SPR) techniques. Importantly, electrochemical applications to biological environments using biomolecule-nanomaterials at the electrode interface may play a lead role in point-of-care settings (POC) in the future [2]. The integration of nanomaterials to biosensing platforms also
may display enzyme mimic properties [3]. Nano-based platforms can facilitate cancer cells capture and release [4], charge transfer reactions [5], enhance the signal read out at the electrode surface [6]. These attributes make nano-based sensing platforms extremely sensitive, significant, over complementary techniques [7].

Iron oxide nanomaterials display enzyme-mimic properties towards chromogenic substances [8]. It is a common knowledge that nanoparticles can replace the enzyme, horseradish peroxidase (HRP) during the oxidation of tetramethylbenzidine (TMB) [9, 10]. The oxide nanomaterials are beneficial as capture agents and catalysts in the detection of autoantibodies and microRNA biological samples [11-14]. Thus, materials with nanoscale dimensions, especially with porous architecture, electrical, and optical properties, are significant in biomedical applications [13, 15, 16].

Not only are electrochemical tools essential for profiling the redox status of a biological or chemical environment, the technique is the gold standard for redox enzymes on thin-film electrode surfaces. Currently, third-generation biosensors involving the integration of porous gold or platinum particles are in demand for high market potential, superior sensitivity, and nanoporous-mimicking activities for signal amplification [17, 18]. We describe in this paper the strategies and evaluation of cancer biomarkers with iron oxide loaded with Au particles (nanozyme), conjugated with antibodies raised against specific biomarkers.

1.1. Biomarker expression levels in breast cancer cells

Biomarkers are cell surface receptors expressed by healthy or cancer cells. However, cancer cells overexpress biological molecules produced at the cell surface. The way to measure the expression is by matching the biomarker to a specific antibody (bioreceptor) it recognises. Depending on the interaction, the signal transduction can either be low or high and is distinct to one cell type. The concept around modification is, therefore, enhancing the signal output using any of the standard techniques. We provide a summary of the cancer biomarkers (scheme 1). T47D cell line was used as the breast cancer cell model and OVCAR3 (ovarian cell line) as the control experiment.
2. Experimental

2.1. Material and methods

The synthesis and characterisation of Au-Fe$_2$O$_3$ (nanozyme) (10 mg), including the loading/releasing effects have been reported previously [19]. Abcam supplied the biotin (Type B) fast conjugation (ab201796) kit. R & D systems, Australia, provided the human antibodies for HER-2, PD-L1, EGFR, and EpCAM. We restored the powdered antibodies to the liquid state just before use at the company's recommendation concentration at 0.50 mg/mL, except for EpCAM human antibody supplied as a liquid and reconstituted at 1.00 mg/mL). R&D Systems, Australia, provided CA-125 antibody used as the capturing agent and the biosensing platform for the negative control experiments. Life Technologies, Australia, supplied the phosphate buffer saline (10 mM, pH 7.4)). Invitrogen, Australia provided the bovine serum albumin (BSA, 50 mg/mL). The stock solution was diluted to 0.1 wt. % before use as a blocking agent. Sigma-Aldrich, Australia, supplied polyethylene glycol (PEG-8000). The 1% PEG solution was used to stabilise antibody molecules during Au-Fe$_2$O$_3$ functionalisation. Sigma-Aldrich, Australia, provided the hydroquinone (HQ) that was used to prepare the stock solution (10 mM). Chem-supply, Australia, supplied hydrogen peroxide (H$_2$O$_2$, 30 wt. %) and potassium ferrocyanide trihydrate (AR grade). The water conductivity provided at 0.025µS/cm. Antibody reconstitution and further dilutions prepared in sterile PBS buffer, except otherwise specified.

Metrohm Dropsens, Spain, supplied all the disposable streptavidin electrodes used on the CH instrument model 700E series workstation. We preconditioned the electrodes at room temperature for 30 minutes. The samples and assays prepared on Eppendorf Thermomixer at 23°C and 300 rpm. Thermo Scientific Heraeus™Pico™17 microcentrifuge tubes were used for the separation of the unbound EpCAM antibodies. The anti-EpCAM/Au-Fe$_2$O$_3$ was extracted by discarding the supernatant solution. Thermo Fisher Scientific supplied Countess II used to count the number of free cells and digital images of cancer cells captured. Invitrogen, Australia, supplied the trypan blue (0.4%, Invitrogen) for the cell staining. Thermo Fischer Scientific, supplied the DynaMag magnetic separation rack used for the washing and isolation of the cells captured.

2.2. Cell culture preparation

We used the subculture cells of the human adenocarcinoma breast and ovarian cancer cell lines of the American Type Culture Collection (ATCC). Dulbecco’s Modified Eagle Medium
DMEM) from Gibco supplied the cell culture nutrient requirements. Thermofisher Scientific supplied the fetal bovine serum (FBS) used for cell growth. Overall, the cell media constituted (90% DMEM, 5% FBS plus 0.5% penicillin-streptomycin). Subculture cells maintained in the incubator at 5% CO₂, 37 °C. We harvested the cancer cells at 80% confluency with TryLE™ Express and retrieve them as pellets at 2500 rpm for 5 min. The cancer cells dispersed in 1 mL PBS buffer solution at pH 7.4.

2.3. EpCAM antibody coating with biotin
Abcam supplied the biotin kit used for anti-EpCAM coating. We added a 1 µL modifier reagent directly to 10 µL EpCAM antibody (10 ng/mL) at room temperature. Then gently mixed biotin powder for another 15 minutes. We stopped the reaction with a quencher reagent (1 µL) and used directly without further purification.

2.4. Cancer cells captured with Au-Fe₂O₃ (nanozyme), Scheme 3(1)
We modified the preparations according to the papers referenced [20-24]. We gently mixed 20 µL nanozyme (1.0 mg/mL) with 10 µL EpCAM antibody (10 ng/mL) for 5 min and added 1.0 µL of 1.0 % PEG. Then stirred the sample mixture on a thermomixer for 30 min at room temperature. The centrifuge process removed the unreacted EpCAM antibody, and Au-Fe₂O₃ / EpCAM antibody conjugate dispersed in 20 µL PBS buffer solution. The nanozyme-EpCAM antibody conjugate was washed twice and dispersed in 10 µL PBS buffer solution containing 1% PEG (1.0 µL). We extracted the aggregate particles with an external magnet and redispersed in 10 µL of T47D cells at the required cancer concentration ranges.

2.5. Cancer cells captured with magnetic beads, MBs, Scheme 3(2)
We vortexed the streptavidin coated MBs (10 mg/mL) for 30 s and transferred 30 µL to a 1.5 mL tube. We mixed 1mg/mL (x10 dilution) of streptavidin coated MBs with 10 µL of biotin coated EpCAM antibody (10 ng/mL) described in section 2.3. After stirring for 30 min on a thermomixer, the mixture was washed on a magnetic rack and dispersed in 10 µL PBS solution. We extracted the aggregate particles with an external magnet and redispersed in 10 µL of T47D cells at the required cancer concentration range.

2.6. Cancer cells captured with double-modified nanozyme and magnetic beads, Scheme 3(1)
The final samples products of schemes 3 (1), nanzyme / anti-EpCAM and 3(2), MBs / anti-EpCAM were used to capture T47D cancer cells according to modifications of published methods [11, 22, 23]. We split 10 µL of harvested cells dispersed in PBS buffer equally and transferred the preconcentrate of schemes 3(1) and 3(2). We merged the two mixtures and mixed on a thermomixer at (23 °C, 300 rpm for one hour). The captured cells were extracted using magnetic separation and redispersed in 10 µL PBS buffer solution.

2.7. Complete assay development

We developed a biorecognition platform for each assay route following the steps taken in sections 2.4 to 2.6. First, we added 10 µL of biotin coated anti-EpCAM (10 ng/mL) to a streptavidin-modified electrode surface and mixed for one hour at 23 °C and 300 revolutions per minute (rpm). The streptavidin modified surface was washed twice with a 5 µL PBS buffer solution to remove the unreacted biotin coated anti-EpCAM. We blocked the non-specific EpCAM antibody on the electrode surface with 0.1% BSA. Then, we transferred the cancer cells captured using the descriptions of sections 2.4 to 2.6 according the general schematic routes (figure 1).

2.8. Direct cancer cells capture on the streptavidin-coated electrode surface

The direct cell capture process follows a modification from a published method [23]. We added a 10 µL of biotin coated anti-EpCAM (10 ng/mL) to a streptavidin-modified electrode surface and mixed for one hour at 23 °C and 300 revolutions per minute (rpm). The electrode surface was washed twice with a 5 µL PBS buffer solution to remove the unreacted biotin coated anti-EpCAM. Subsequently, we blocked the non-specific EpCAM antibody on the electrode surface with 0.1% BSA concentration for 10 min. Then, we transferred 10 µL of T47D cells dispersed in PBS at (10^5 cells /mL). The assay was incubated on the thermomixer for one hour and washed sparingly with (scheme not indicated).

3. Results and discussion

We investigated the platforms for cancer cells capture, compared the amperometry performance, and profiled biomarker expression levels using a breast cancer model. T47D cell line was used as the ideal breast cancer model because the cancer cells have more distinctive molecular characteristics than the MCF-7 cell line. MCF-7 is also susceptible to
progesterone (PR) of the luminal A subtype breast cancer family [25]. Luminal T47D cells also displays tightly cohesive mass structures [26].

In this study, we used T47D cells for the positive experiment and OVCAR-3 for the control experiment (scheme 1). Since EpCAM expression in cancer cells is significantly high [27], we used anti-EpCAM/nanozyme as the dispersible capture agent to recognise T47D cells expression of EpCAM. Additionally, we evaluated the positive HER-2 expression of T47D breast cancer type using an HER-2 antibody. Importantly, HER-2 forms heterodimers easily with EGFR, and T47D breast cancer type is known to display a preponderance of the protein [28]. However, PD-L1 (programmed cell death) receptor in breast cancer types, is associated with large size tumour, estrogen receptor, ER (-), progesterone receptor, PR-, HER-2(+) in HER-2 enriched subtype [29]. CA-125 is a significant biomarker in ovarian cancer patients, and 90% of women with the disease have elevated serum levels [30].

We incorporated nanomaterials as our capture cargo to increase (i) the surface area (ii) provide high surface activity (iii) provide good adsorption capacity (iv) concentrate the analytes and (v) amplify the signal. To this end, we developed the biorecognition platforms by immobilising biotin (Bo.) coated antibodies to streptavidin-modified electrodes (STE). The following modified electrodes were used, STE/Bio. (i) Anti-HER2 (ii) Anti-EGFR (iii) CA-125 antibody and (iv) Anti-PD-L1.

The general preparation route before detection (scheme 2) consisted of (I) nanomaterial functionalisation (II) cell capture (III) biorecognition staging and (IV) electrochemical profiling. The inclusion of PEG to the nanomaterials and biomolecules confer stability to the molecular assemblies. PEG can also increase the antibody hydration, thereby enhancing the stability of the conjugate during the PEGylating process [23, 31]. PEG functionalisation increased the stability of the conjugation (antibody—PEG—nanomaterials).

The biosensing platform involves the formation of non-covalent interactions between biotin and the streptavidin modified electrode surface. The addition of a BSA solution blocks any non-specific protein-surface and protein-protein interactions that may hinder assay performance during use as a biorecognition platform [32, 33]. In this report, we used a 0.1 % BSA concentration solution for 10 min at room temperature incubation as the optimal blocking condition. While other blocking agents including, Tween 20 [34], PEG [31], milk proteins [35], and serum albumins [36] are equally good, BSA participation as a blocking agent shows the least steric hindrance during protein-protein binding [31]. Adopting this approach
increased the sensitivity and specificity of our biorecognition platforms. The different pathways initially considered for the comparative performance of the best performing breast cancer assays (scheme 3) is in Table 1, with a more elaborate discussion elsewhere (figure 4).

The differential pulse voltammetry (DPV) profile (figure 1) measured the serial dilution of BSA concentrations on the surface of the biorecognition platform. We obtained the layer by layer interface with the stepwise addition of a 2 mM \([\text{Fe (CN)}_6]^{4-/3-}\) of an electrolyte solution. The first layer formed the profile of the biorecognition platform after adding a redox probe, \(\text{Fe} [[\text{CN})_6]^{3-/4-}\), with a successive dilution of BSA concentration (figure 1a) and linear range of BSA concentration (figure 1b). The profiling and calibration of the BSA concentration confirmed two things. First that the biosensing platform had a functional signal readout as the drop in current correlated to the increase in BSA concentration (figure 1a). Second, the linear BSA range indicated the acceptable concentration range for use as a blocking agent (figure 1b). We used a 0.1 % BSA in all the experiments to minimise steric hindrance and increase the specificity and sensitivity of the biorecognition platform.

A similar DPV profile for the reactant molecules (figure 2) indirectly or directly attached to the surface of the same biorecognition platform showed a current decrease as the biological concomitant moieties increased on the electrode surface. The Faradaic current corresponds to the partial flow of electrons [37, 38]. As the concentration of biomolecule moieties increased, electrons access to the surface were partially hindered, leading to a drop in the current response. The limitations with the DPV technique are that the sensitivity increases with a small group of reactants and is not suitable for copious reactants or minute reactants with no detectable signal[39]. Interestingly, amperometry biosensors depend mostly on the electrode properties, with signal response near to the biosensing electrode[6].

We obtained the amperometry response profile (figure 3) by adding 35 µL of 1 mM HQ to the test sample to give a momentary baseline signal. Then followed it with the addition of 35 µL of 10 mM \(\text{H}_2\text{O}_2\) (30 % v/v). The encounter of HQ solution with \(\text{H}_2\text{O}_2\) on the electrode surface leads to a charge transfer of electrons. The electron transfer takes place during the oxidation of HQ to Q. The lift (or jump) in signal response is at the point of addition of \(\text{H}_2\text{O}_2\). The returned plateau (stabilised signal) is relative to the HQ response, and the difference is the amperometry response of the assay.

The inclusion of nanomaterials to a biosensor is to amplify the signal and concentrate the analytes for detection. The Amperometry biosensor depends on the current resulting from
the redox reaction of a biorecognition platform, and it is the source that provides the specific, quantitative analytical information. Nanomaterials inclusion in cancer-based assays tends to produce higher current responses in amperometry technique. Kung et al. [40], showed the oxidation of HQ to Q increased in the presence of Fe oxide derivative as the concentration of hydroquinone decreased. Also, oxides with a higher surface area, oxidise twice as much HQ to quinone and pH had little or no effect on the oxidation of hydroquinone in the presence of an iron oxide loaded surface material [40]. Unexpectedly, the amperometry profile (figure 4, table 1) indicated a lower response in Scheme 3(3), $40 \mu A$ than the nanozyme assay in Scheme 3 (1), $100 \mu A$. There was no signal response in Scheme 3(2) containing MBs, suggesting there was a partial flow of electron from nanozyme in the double-modified nanomaterials in Scheme 3(3). We also suggest, replacing the biosensing interface with Bio.anti-HER2 in Scheme 3(3) may increase the dual-signal amplification performance. The direct capture method with EpCAM immobilised STE, produced a relatively low net signal response ($5 \mu A$). Nonetheless, Scheme 3(1) pathway with nanozyme produced the highest signal response ($100 \mu A$).

We calculated the amperometry responses by considering the response without cells (control), response with cells and the net response of the biosensing platform (figure 4) according to the following calculations,

\[
\text{Amperometry response, } \text{Amp}_{(R)} = I_R (\text{HQ/H}_2\text{O}_2 \text{ stabilised response}) - I_R (\text{HQ addition}) \quad (1)
\]

where $I_R$ (HQ/H$_2$O$_2$ stabilised response) is the stabilised current response at the addition of HQ/H$_2$O$_2$ and $I_R$ (HQ addition is the current response at the addition of HQ only). Here, we noted that HQ addition induced different current responses, attributed to the different interface layers. Therefore, subtracting equation 1 removed the solvent background and other interfering signals during the redox process. The net amperometry response,

\[
\text{Amperometry response with cells} - \text{Amperometry response without cells} \quad (2)
\]

The net signal response corresponds to the amperometry response of the cancer biomarker profiling.

We showed nanozyme capture efficiency of cancer cells (figures 5a and 5b) and post-capture sub-culture (figure 5c) at different cell concentrations (10$^5$ to 10 cells/mL). The green colour mapping (figure 5c) were the viable cells and the red colour mapping the dead cells. Interestingly, we observed viable cells growth of post capture release after 6 hrs in a tissue
culture flask (figure 5c). The result from Figure 5 showed the practicability of using the nanozyme capture platform in post-capture culture expansions.

The precursor derivative of nanozyme without the gold particles demonstrate great potential as efficient transport and control release of drug. Noteworthy, gold particles loading to iron oxide (nanozyme structure) provides fast adsorption of antigen and antibodies on the gold particles surface. The incubation of cells in either free serum or serum proteins (BSA) may either increase the cellular uptake of the nanoparticles via endocytosis [41] or inhibit the cellular uptake of the nanoparticles using the so-called "scavenger receptors" in serum-containing samples [42]. The present study considers the cell surface attachment to Au particles (Au-Fe₂O₃) as the probable mechanism and not endocytosis.

The calibration plot (figure 6b) was used to calculate the limit of detection, LOD, and the limit of quantitation, LOQ, using the direct amperometry response for the serial dilution of T47D cells in the presence of HQ/H₂O₂ (figure 6a). We obtained the LOD and LOQ calculations from a linear regression plot [43]. Then we used the plot as the model to compute the LOD and LOQ as follows,

\[ y = ax + b \]  \hspace{1cm} (3)

\[ \text{LOD} = \frac{3S}{a} \]  \hspace{1cm} (4)

\[ \text{LOQ} = \frac{10S}{a} \]  \hspace{1cm} (5)

S is the standard deviation of the response (represents the standard error in this report), and \( a \) is the slope of the calibration plot within the dynamic range for the serial dilution of cell concentration. Compared to the LOD of the existing biosensor platforms (table 2), we obtained a significantly low (LOD 0.4 μM L⁻¹ and LOQ, 4 mL⁻¹), with good reproducibility within the linear range of cancer cell detection.

We also investigated the amperometry responses for the positive and negative experiments (figure 7). There was increase in signal response with the biosensing platform as STE/Bio.anti-HER in the presence of T47D cells. However, control assays (negative control) with OVCAR3, no cancer cells, or a negative marker as a capture agent, or as part of a biosensing platform, produced relatively low signal responses, equivalent to approximately one-sixth in the output response of the positive setup assay. Since the immediate signal response of a negative test is not necessarily a zero response [6], the direct amperometry responses for the negative control set up (figure 7b) were within experimental measurements.
. The negative control can only be zero or insignificant using the net amperometry response calculation in equations 1 and 2.

We also investigated the mean amperometry responses using different biosensing interfaces (figure 8), biotinylated (I) anti-HER2, (II) anti-EGFR, and (III) anti-PD-L1, to profile biomarker expression levels in T47D cells. The cancer cells captured, T47D-Anti.EpCAM-Au-Fe₂O₃ remained the same during the amperometry measurement. Interestingly, we observed significant amperometry responses. The biosensing platform with anti-HER 2 responded with the highest signal, suggesting the presence of HER2 (+). The low PD-L1 signal response may suggest unidentified biomarkers of ER (-), PR (-), and high progesterone (PR+) levels. In a similar work conducted by Cahall ([53] using a flow cytometry analysis, the EGFR: HER-2 obtained, 1:2 fold expression detection with the flow cytometry method [53]. We got a 1:55 fold expression detection. The PD-L1 expression, as opposed to EGFR expression, suggests a slight upregulation in the presence of (HQ/BQ system), which may be due to cytotoxic local immune response [29].

4. Conclusions

The cancer assay developed using nanozyme and anti-HER2 antibody as the biosensing interface exhibited high sensitivity and low LOD. We obtained a LOD value, 0.4 UmL⁻¹ and LOQ, 4 UmL⁻¹. Compared to the existing biosensor platforms available, the streptavidin-modified electrode surface reproducibility is significantly high. We also obtained a wide capturing range (> 80 %, from 10-10⁵ cells / mL in PBS buffer, pH 7.4) for the T47D cancer cells. We showed the practicability of a post-capture expansion of the cancer cells, which may be useful in the evaluation of the phenotypes. The selective responses obtained by changing the biorecognition platform is proof of concept that this platform is suitable for cancer biomarker profiling.

Data accessibility. The authors confirm that the data supporting the findings of this study are available within the results section of this paper.

Authors’ contributions. V.A carried out the laboratory work and data analysis, participated in the design of the study, coordinated the study and draft the manuscript; M.J.A.S participated in the design of the study, coordinated the study and helped draft the manuscript; T.H.K coordinated the manuscript and helped draft the manuscript; C.L.B coordinated the manuscript and helped draft the manuscript; Y.Y. provided the nanozyme and the technical information about the material; I.E.C. coordinated the study and helped draft the manuscript. All authors gave final approval for publication.

Competing interests. We have no competing interest.
Funding. V.A acknowledges research grant from the Griffith University towards doctoral programme.

Acknowledgements. V.A acknowledges the Griffith University for the GUPR and GUIPR scholarships.

References


### Table 1. Cell capture platform performance

<table>
<thead>
<tr>
<th>Method</th>
<th>Biorecognition platform</th>
<th>Cell capture</th>
<th>Net amperometry response / ( \mu A )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scheme 3 (1)</td>
<td>STE/Bio.Anti-HER2</td>
<td>T47D-Anti.EpCAM-Au-Fe(_2)O(_3)</td>
<td>(~100)</td>
</tr>
<tr>
<td>Scheme 3 (2)</td>
<td>STE/Bio.Anti-EGFR</td>
<td>T47D-Bio.Anti-EpCAM-STE.MBs</td>
<td>(~40)</td>
</tr>
</tbody>
</table>

Direct cell capture with STE

<table>
<thead>
<tr>
<th>Biorecognition platform</th>
<th>Cell capture</th>
<th>Net amperometry response / ( \mu A )</th>
</tr>
</thead>
<tbody>
<tr>
<td>STE/Bio.Anti-EpCAM</td>
<td>T47D</td>
<td>(~5)</td>
</tr>
</tbody>
</table>

STE, streptavidin modified screen printed electrode. Bio. (Biotinylated).

### Table 2. Limit of detection of the existing biosensor platforms

<table>
<thead>
<tr>
<th>Breast cancer type/target</th>
<th>Biosensor specifications</th>
<th>Linear range (cells mL(^{-1}))</th>
<th>Detection limit (cells mL(^{-1}), LOD)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-7 (MUC1)</td>
<td>Porous GO/Au composites and PtFe alloy</td>
<td>(10^5 - 5 \times 10^7)</td>
<td>38</td>
<td>[44]</td>
</tr>
<tr>
<td>MCF-7 (MUC1)</td>
<td>HRP/MUC1/aptamer1/Au electrode</td>
<td>(10^2 - 1 \times 10^7)</td>
<td>100</td>
<td>[45]</td>
</tr>
<tr>
<td>MCF-7 (MUC1 &amp; CEA)</td>
<td>MUC1/aptamer/MCF-7/anti-CEA-Cds NPs</td>
<td>(10^8 - 10^7)</td>
<td>(3.3 \times 10^2)</td>
<td>[46]</td>
</tr>
<tr>
<td>MCF-7 (EpCAM)</td>
<td>Anti-EpCAM/LC-SPDP/Au electrode</td>
<td>(10^8 - 10^5)</td>
<td>(10^5)</td>
<td>[47]</td>
</tr>
<tr>
<td>MCF-7 (HER-2)</td>
<td>Anti-cerbB2/polypyrrole-NHS/GCE</td>
<td>(10^3 - 10^4)</td>
<td>100</td>
<td>[48]</td>
</tr>
<tr>
<td>SK-BR-3 (HER-2)</td>
<td>S6 aptamer/AuNPs/ZnO/IITO electrode</td>
<td>(10^2 - 10^5)</td>
<td>58</td>
<td>[49]</td>
</tr>
<tr>
<td>SK-BR-3 (HER-2)</td>
<td>NFG/AuNPs/PANI</td>
<td>(10 - 5 \times 10^6)</td>
<td>2</td>
<td>[50]</td>
</tr>
<tr>
<td>SK-BR-3 (HER-2)</td>
<td>Hydrazine/AuNPs/aptamer</td>
<td>(50 - 2 \times 10^4)</td>
<td>26</td>
<td>[51]</td>
</tr>
<tr>
<td>MBA-MB-231 &amp; T47D (H(_2)O _ traces in cells)</td>
<td>AuPtPd/rGO-modified GCE</td>
<td>0.005 (\mu M - 6.5) mM</td>
<td>2 nM</td>
<td>[52]</td>
</tr>
<tr>
<td>T47D (EpCAM &amp; HER-2)</td>
<td>Anti-EpCAM/Au-Fe(_2)O(_3)/Bio.Anti-HER2/STE</td>
<td>(10 - 10^5)</td>
<td>(0.4 ) U mL(^{-1}) (LOD), (4 ) U mL(^{-1}) (LOQ)</td>
<td>This work*</td>
</tr>
</tbody>
</table>

*LOD, is the lowest concentration of the analyte detected in the sample but not quantitated under the stated condition of the test. LOQ, is the lowest concentration of the analyte determined with acceptable precision and accuracy under the stated conditions of test.
**Scheme 1.** Classification of breast cancer biomarkers and assay profiling. T47D cell line is from the human breast cancer cells, and OVCAR 3 cell line is from the human ovarian cancer cells. The scheme shows the basic concept for the classification of biomarkers discussed in this paper. EpCAM (Epithelial Cell Adhesion Molecule), EGFR (Epithelial Growth Factor Receptor), HER-2 (Human Epidermal Growth Factor Receptor 2), PD-L1 (Programmed Death-Ligand 1), PD-1 (Programmed Cell Death Protein 1), CA-125 (Cancer Antigen, 125), ER (Oestrogen Receptor), PR (Progesterone Receptor).

**Scheme 2.** The stages in the electrochemical detection of cancer cells (1) Nanozyme functionalised with the EpCAM antibody (capture agent) (2) Dispersed the capture agent in cancer cells containing PBS buffer solution at pH 7.4. We extracted the cancer cells with an external magnet (3) Biosensing platform developed. (4) Transferred the cancer cells captured on the recognition platform (5) Electrochemical detection and profiling of cancer cells using the amperometry method.
Scheme 3. Pathways to assay schemes. Scheme 3(1) biotinylated anti-HER2/streptavidin-modified electrode. Scheme 3 (2) and Scheme 3 (3) biotinylated anti-EGFR/streptavidin-modified electrode.
Figure 1. The biosensing performance of the platform was characterised electrochemically with DPV. The biosensing part, biotinylated anti-HER2 and streptavidin-modified electrodes. Figure 1(a) BSA % at different concentrations (b) linear range of BSA concentration. The DPV experiment monitored in 2.5 mM \([\text{K}_3 \text{Fe (CN)}_6] \) and 2.5 mM \([\text{K}_4 \text{Fe (CN)}_6] \) electrolyte solution.

Figure 2. The DPV method was used to monitor the different stages of assay development. The streptavidin-modified electrode conjugated to biotinylated HER-2 antibody, with the subsequent addition of 0.1% BSA concentration for 10 min. Finally, the cells captured (anti-EpCAM/Au-Fe$_2$O$_3$ dispersed in PBS buffer containing T47D cells). The DPV experiment monitored in 2.5 mM \([\text{K}_3 \text{Fe (CN)}_6] \) and 2.5 mM \([\text{K}_4 \text{Fe (CN)}_6] \) electrolyte solution.
Figure 3. Amperometry (current versus time plot) response in the presence of cancer cells using 1 mM HQ / 10 M H₂O₂.

Figure 4. Assay performances in the presence of 1 mM HQ / 10 M H₂O₂. The biosensing interfaces, biotinylated anti-HER-2 as Scheme 3(1). Schemes 3(2) and 3(3) as biotinylated anti-EGFR. Biotinylated anti-EpCAM used in direct cell capture. Relative standard deviation (RSD) of 5.0 % (n=3) *Net response was unobtainable in Scheme 3(2) due to no current difference in with/without cells.
Figure 5. The capture efficiency of cancer cells and the expansion of cancer cells released (a) The capture efficiency was enumerated directly using an automated cell counter (b) numbered 1 to 5, the photomicrographs of T47D breast cancer cells captured at different serial dilution concentrations (10 to $10^5$ cells/mL (scale bar = 500 µm). Numbered 6, digital images of viable cells captured (green colour dots as viable cells and red color dots as dead cells) (c) Post capture expansion of T47D cancer cells in a standard tissue flask (scale bar = 100 µm).
Figure 6. (a) The direct amperometry responses (current versus time) obtained for breast cancer cells captured at different serial dilution concentrations (10 to $10^5$ cells/mL). The responses measured in 1 mM HQ / 10 M H$_2$O$_2$. Relative standard deviation (RSD) of 5.0 % (n = 3). The calibration plot in Figure 6b was used to calculate LOD and LOQ values. The slope of the graph, 5.4, and the standard error of slope, 0.7. The linear regression ($R^2$), 0.93. We considered the net responses in the LOD and LOQ calculations.

![Figure 6(a)](image1)

![Figure 6(b)](image2)
Figure 7. The direct amperometry responses of current for (a) I. Positive experiment and II-V negative controls. (b) Direct amperometry (i-t) profile of the negative controls. The responses measured in the presence of 1 mM HQ / 10 M H₂O₂. Sensing platforms, biotinylated: anti-HER and CA-125 antibody. CA 125 is a cancer antigen marker for ovarian cancer cells. Relative standard deviation (RSD) of 5.0 % (n=3).
Figure 8. Amperometry responses from the biomarker expressions in the presence of 1 mM HQ / 10 M H$_2$O$_2$, with T47D cancer breast cancer cells. Relative standard deviation (RSD) of 5.0% (n = 3).
Supplementary information

Scheme S1. Cancer cells captured with nanozyme. The biosensing platform: biotinylated anti-HER2 integrated on the streptavidin electrode surface.

Scheme S2. Cancer cells captured with magnetic beads, MBs. The biosensing platform: biotinylated anti-EGFR integrated on the streptavidin electrode surface.

Scheme S3. Cancer cells captured with double-modified nanomaterials, MBs and nanozyme. The biosensing platform: biotinylated anti-EGFR integrated on the streptavidin electrode surface.
Scheme S4. Direct cancer cells capture. Cancer cells captured directly with anti-EpCAM. HRP-anti-HER2 was used to enhance the signal response. The biosensing platform: biotinylated anti-EpCAM integrated on the streptavidin electrode surface.

Schemes. Schematic representation of the different assays developed. No scale considerations (not drawn to scale) in all the schemes and to the number of cancer cells present on the electrode surface.
Figure S1. DPV method was used to monitor the fabrication of platforms during the different stages of assay development. Streptavidin-modified electrode was conjugated to biotinylated: (a) anti-HER (b) EGFR and (c) EpCAM. BSA was added for 10 min. Finally, in a and b cancer cells captured (T47D cancer cells) were added, except for (c) that cells were incubated directly onto the modified electrode surface. The DPV experiment was monitored in PBS solution containing 2.5 mM [K₃Fe(CN)₆] and 2.5 mM [K₄Fe(CN)₆].

Figure S2. Amperometry responses were measured in the absence and presence of cancer cells using 1 mM HQ / 10 M H₂O₂. The following biomarkers investigated along with their corresponding antibodies: EpCAM (Epithelial Cell Adhesion Molecule), EGFR (Epithelial Growth Factor Receptor), HER-2 (Human Epidermal Growth Factor Receptor 2), PD-L1 (Programmed Death-Ligand 1), PD-1 (Programmed Cell Death Protein 1), CA-125 (Cancer Antigen, 125). In principle, oxides with a higher surface area such as n anozyme will produce as much Q from HQ. The pH has no influence on the oxidation of hydroquinone in the presence of an iron oxide loaded surface material. We observed a rapid conversion of hydroquinone (HQ) to benzoquinone (Q) as the concentration of HQ decreased in the presence of Au₂-Fe₂O₃.
Figure S3. Stabilised amperometry lines in the absence and presence of cancer cells for Schemes 1 to 4 using 1 mM HQ / 10 M H₂O₂. Biotinylated: (a) anti-HER2 (b), (c) anti-EGFR and (d) anti-EpCAM integrated on streptavidin electrode interface. Concentration of cells, 10⁵ cells/mL. The cells were incubated directly on the biorecognition platforms. The unattached cells washed with PBS. We calculated the net amperometry for each response using, Amperometry response, \( \text{Amp}(R) = I_R (\text{HQ/H}_2\text{O}_2 \text{ stabilised response}) - I_R (\text{HQ addition}) \). The line response for HQ addition is shown in Figure S2.
**Figure S4.** Assay performances in the presence of 1 mM HQ / 10 M H$_2$O$_2$. Sensing platforms include biotinylated: anti-HER2 (Scheme 1) anti-EGFR (Schemes 2 and 3) and anti-EpCAM (Scheme 4) integrated on streptavidin electrode surface. Relative standard deviation (RSD) of 5.0 % (n=3). *Net response was unobtainable due to no current difference in with/without cells for scheme 2.

**Acknowledgements:** V.A thanks Griffith University for the GUPR and GUIPR scholarships.

Data accessibility. The authors confirm that the data supporting the findings of this study are available within the results section of this paper.

**Competing interests.** We have no competing interest.